Dr. Reddy's Lab launches Tobramycin Inhalation Solution in US market
25th Jun 2019

Dr. Reddy's Laboratories has launched Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the US Food and Drug Administration (USFDA).

According to IQVIA Health, the TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019. The company’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.